Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies

Study Published in Immunity in Collaboration with The Scripps Research Institute and IAVI April 25, 2014 Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the publication of data in the May issue of Immunity regarding antibodies with significant potency and breadth against human immunodeficiency virus (HIV). The study, titled “Broadly neutralizing HIV antibodies define a novel glycan-dependent epitope on the …

HIV & AIDS: Facts, figures, and vaccines

This month on Vaccine Nation we’re going to be taking a look at HIV/AIDS vaccines. In the coming weeks we will  look at the current generation of HIV vaccines and the different approaches developers are taking in their attempts to defeat this notorious virus. (The infographic may take a few seconds to load) If you have trouble viewing this inforgraphic …